ホーム>>Signaling Pathways>> Proteases>> Drug Metabolite>>Etilevodopa hydrochloride

Etilevodopa hydrochloride

カタログ番号GC39757

エチレボドパ (L-ドーパ エチル エステル) 塩酸塩は、レボドパのエチル エステル プロドラッグであり、胃腸管内で非特異的エステラーゼによってレボドパとエタノールに急速に加水分解されます。

Products are for research use only. Not for human use. We do not sell to patients.

Etilevodopa hydrochloride 化学構造

Cas No.: 39740-30-2

サイズ 価格 在庫数 個数
10mM (in 1mL Water)
$50.00
在庫あり
5mg
$45.00
在庫あり
10mg
$72.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester prodrug of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable prodrug as it facilitates CNS penetration and delivers dopamine[1][2][3].

[1]. Djaldetti R, et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov-Dec;26(6):322-6. [2]. Blindauer K, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63(2):210-6. [3]. Haddad F, et al. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2017 Dec 25;23(1). pii: E40.

レビュー

Review for Etilevodopa hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Etilevodopa hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.